BR100 Increased By (1.41%)
BR30 Increased By (1.74%)
KSE100 Increased By (1.32%)
KSE30 Increased By (1.4%)
AGHA 6.08 Increased By ▲ 0.05 (0.83%)
BECO 3.87 Increased By ▲ 0.01 (0.26%)
BML 60.16 Decreased By ▼ -0.84 (-1.38%)
BOP 28.96 Increased By ▲ 0.87 (3.1%)
CNERGY 11.89 Increased By ▲ 0.15 (1.28%)
CSIL 5.33 Increased By ▲ 0.03 (0.57%)
FCCL 55.95 Increased By ▲ 1.49 (2.74%)
FFL 13.15 Increased By ▲ 0.08 (0.61%)
FNEL 1.17 Increased By ▲ 0.06 (5.41%)
KEL 5.81 Increased By ▲ 0.18 (3.2%)
KOSM 5.40 Increased By ▲ 0.06 (1.12%)
LOTCHEM 24.13 Increased By ▲ 0.30 (1.26%)
MLCF 95.09 Increased By ▲ 2.11 (2.27%)
NBP 167.60 Increased By ▲ 4.40 (2.7%)
NCPL 49.20 Increased By ▲ 0.93 (1.93%)
NPL 50.55 Increased By ▲ 0.84 (1.69%)
OGDC 307.11 Increased By ▲ 3.48 (1.15%)
PACE 9.12 Increased By ▲ 0.15 (1.67%)
PAEL 32.60 Increased By ▲ 0.69 (2.16%)
PIBTL 13.05 Increased By ▲ 0.31 (2.43%)
PPL 215.90 Increased By ▲ 2.99 (1.4%)
PRL 85.65 Increased By ▲ 1.31 (1.55%)
PTC 45.40 Increased By ▲ 0.41 (0.91%)
SSGC 23.23 Increased By ▲ 0.40 (1.75%)
TBL 8.96 Increased By ▲ 0.08 (0.9%)
TELE 6.60 Increased By ▲ 0.10 (1.54%)
TPL 25.05 Increased By ▲ 0.79 (3.26%)
TPLP 12.45 Increased By ▲ 0.46 (3.84%)
TREET 23.50 Increased By ▲ 0.36 (1.56%)
TRG 52.25 Increased By ▲ 0.78 (1.52%)
By

MANILA: The Philippines received 600,000 vaccine doses from China Sunday, kickstarting the country’s inoculation drive despite concerns over the Sinovac jab’s effectiveness. Top government officials and health workers will be the first on Monday to receive the Chinese-made vaccine — called CoronaVac — just days after the drug regulator approved it for emergency use.

President Rodrigo Duterte, whose government has been under fire over delays in procuring vaccines, oversaw the delivery of the doses at a military air base.

Around 525,000 doses of AstraZeneca jab, distributed as part of the global Covax global inoculation programme, were also supposed to arrive on Monday, but Health Secretary Francisco Duque later said the shipment will be delayed for a week due to global supply problems.

The regulator did not recommend CoronaVac for healthcare workers due to its comparatively low efficacy.

Comments

Comments are closed for this article.